title,authors,countries,abstract,publication_date,doi,author_disclosures
"Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study",Ignace  Vergote; Els  Van Nieuwenhuysen; Roisin E.  O'Cearbhaill; Anneke  Westermann; Domenica  Lorusso; Sharad  Ghamande; Dearbhaile C.  Collins; Susana  Banerjee; Cara A.  Mathews; Christine  Gennigens; David  Cibula; Krishnansu S.  Tewari; Kristine  Madsen; Fatih  Köse; Amanda L.  Jackson; Ingrid A.  Boere; Giovanni  Scambia; Leslie M.  Randall; Azmat  Sadozye; Jean-François  Baurain; Eelke  Gort; Michal  Zikán; Hannelore G.  Denys; Nelleke  Ottevanger; Frédéric  Forget; Camilla  Mondrup Andreassen; Lamar  Eaton; Michael J.  Chisamore; Leonardo  Viana Nicacio; Ibrahima  Soumaoro; Bradley J.  Monk,Belgium; Belgium; NY; the Netherlands; Italy; GA; Ireland; United Kingdom; RI; Belgium; Czech Republic; CA; Denmark; Turkey; OH; the Netherlands; Italy; VA; United Kingdom; Belgium; the Netherlands; Czech Republic; Belgium; the Netherlands; Belgium; Denmark; NJ; NJ; WA; NJ; AZ,"Purpose: Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in combination with bevacizumab, pembrolizumab, or carboplatin for recurrent or metastatic cervical cancer (r/mCC).

Methods: This open-label, multicenter study (ClinicalTrials.gov identifier: NCT03786081) included dose-escalation arms that assessed dose-limiting toxicities (DLTs) and identified the recommended phase II dose (RP2D) of TV in combination with bevacizumab (arm A), pembrolizumab (arm B), or carboplatin (arm C). The dose-expansion arms evaluated TV antitumor activity and safety at RP2D in combination with carboplatin as first-line (1L) treatment (arm D) or with pembrolizumab as 1L (arm E) or second-/third-line (2L/3L) treatment (arm F). The primary end point of dose expansion was objective response rate (ORR).

Results: A total of 142 patients were enrolled. In dose escalation (n = 41), no DLTs were observed; the RP2D was TV 2 mg/kg plus bevacizumab 15 mg/kg on day 1 once every 3 weeks, pembrolizumab 200 mg on day 1 once every 3 weeks, or carboplatin AUC 5 on day 1 once every 3 weeks. In dose expansion (n = 101), the ORR was 54.5% (n/N, 18/33; 95% CI, 36.4 to 71.9) with 1L TV + carboplatin (arm D), 40.6% (n/N, 13/32; 95% CI, 23.7 to 59.4) with 1L TV + pembrolizumab (arm E), and 35.3% (12/34; 19.7 to 53.5) with 2L/3L TV + pembrolizumab (arm F). The median duration of response was 8.6 months, not reached, and 14.1 months, in arms D, E, and F, respectively. Grade ≥3 adverse events (≥15%) were anemia, diarrhea, nausea, and thrombocytopenia in arm D and anemia in arm F (none ≥15%, arm E).

Conclusion: TV in combination with bevacizumab, carboplatin, or pembrolizumab demonstrated manageable safety and encouraging antitumor activity in treatment-naive and previously treated r/mCC.",2023-12-20,JCO.23.00720,"[{'Author': 'Ignace Vergote', 'Disclosures': ['Consulting or Advisory Role: AstraZeneca, Elevar Therapeutics, Genmab, Immunogen, Jazz Pharmaceuticals, Mersana, MSD, Novocure, Sotio, Verastem, Zentalis, Roche, Agenus, Eisai, Novartis, Seagen, Akeso Biopharma, Bristol Myers Squibb, Deciphera, Exelixis, GlaxoSmithKline, Karyopharm Therapeutics, Oncoinvent, OncXerna Therapeutics, Regeneron, Sanofi', 'Research Funding: Roche (Inst), Amgen (Inst), Oncoinvent (Inst)', 'Travel, Accommodations, Expenses: Karyopharm Therapeutics, Genmab, Novocure']}, {'Author': 'Els Van Nieuwenhuysen', 'Disclosures': ['Consulting or Advisory Role: Regeneron (Inst), Oncoinvent', 'Research Funding: AstraZeneca (Inst), Lilly (Inst), GlaxoSmithKline (Inst), Merck (Inst), Seagen (Inst)']}, {'Author': ""Roisin E. O'Cearbhaill"", 'Disclosures': ['Honoraria: GlaxoSmithKline, Curio Science, MJH Life Sciences, MJH/PER', 'Consulting or Advisory Role: Seagan, Aptitude Health, Fresenius Kabi, GlaxoSmithKline, Bayer, Regeneron, Carina Biotech, Immunogen, R-Pharm, GOG Foundation, Miltenyi Biotec, 2seventy bio', 'Research Funding: Juno Therapeutics (Inst), Sellas Life Sciences (Inst), Ludwig Institute for Cancer Research (Inst), TapImmune Inc (Inst), TCR2 Therapeutics (Inst), Regeneron (Inst), Genmab (Inst), Atara Biotherapeutics (Inst), GlaxoSmithKline (Inst), AstraZeneca/Merck (Inst), Syndax (Inst), Genentech (Inst), Kite/Gilead (Inst), GOG Foundation (Inst), Merck/Genentech (Inst), Acrivon Therapeutics (Inst), Bristol Myers Squibb (Inst)', 'Travel, Accommodations, Expenses: Hitech Health, Gathering Around Cancer, Society of Gynecologic Oncology', 'Other Relationship: JAMA Oncology', ""Uncompensated Relationships: Children's Medical Research Foundation (CMRF)"", 'Open Payments Link: https://openpaymentsdata.cms.gov/physician/785539']}, {'Author': 'Domenica Lorusso', 'Disclosures': ['Consulting or Advisory Role: PharmaMar, AstraZeneca, Clovis Oncology, GlaxoSmithKline, MSD, Genmab, Seagen, Immunogen, Oncoinvest, Corcept Therapeutics, Sutro Biopharma, Novartis', ""Speakers' Bureau: AstraZeneca, Clovis Oncology, GlaxoSmithKline, MSD, PharmaMar, ImmunoGen, Seagen, Genmab"", 'Research Funding: PharmaMar (Inst), Clovis Oncology (Inst), GlaxoSmithKline (Inst), MSD (Inst), AstraZeneca (Inst), Genmab (Inst), Seagen (Inst), Immunogen (Inst), Incyte (Inst), Novartis (Inst), Roche (Inst)', 'Travel, Accommodations, Expenses: AstraZeneca, Clovis Oncology, GlaxoSmithKline', 'Uncompensated Relationships: Gynecological Cancer InterGroup']}, {'Author': 'Sharad Ghamande', 'Disclosures': ['Consulting or Advisory Role: Seagen', ""Speakers' Bureau: Tesaro/GSK, Eisai"", 'Research Funding: Jounce Therapeutics (Inst), Astellas Pharma (Inst), Akeso Biopharma (Inst), Merck Serono (Inst), Incyte (Inst), Ellipses Pharma (Inst), Aravive (Inst), GlaxoSmithKline (Inst), Merck (Inst), Roche (Inst), Genentech (Inst), Takeda (Inst), Seagen (Inst), Advaxis (Inst), Bristol Myers Squibb (Inst), Clovis Oncology (Inst), AbbVie (Inst), Tesaro (Inst)']}, {'Author': 'Dearbhaile C. Collins', 'Disclosures': ['Honoraria: Pfizer, Genmab, SeaGen, GlaxoSmithKline, Roche', 'Consulting or Advisory Role: Seagen, MSD', 'Research Funding: Pfizer (Inst), Roche (Inst)', 'Travel, Accommodations, Expenses: Roche/Genentech']}, {'Author': 'Susana Banerjee', 'Disclosures': ['Stock and Other Ownership Interests: Perci Health', 'Honoraria: AstraZeneca, GlaxoSmithKline, Clovis Oncology, Pfizer, Immunogen, MSD Oncology, Mersana, Roche, Takeda, Amgen, Novocure', 'Consulting or Advisory Role: GlaxoSmithKline, MSD Oncology, Mersana, AstraZeneca, Seagen, OncXerna Therapeutics, Shattuck Labs, Immunogen, Regeneron, Novartis, Epsilogen', 'Research Funding: GlaxoSmithKline (Inst), AstraZeneca (Inst)', 'Travel, Accommodations, Expenses: GlaxoSmithKline, AstraZeneca, Verastem']}, {'Author': 'Cara A. Mathews', 'Disclosures': ['Research Funding: AstraZeneca (Inst), Tesaro/GSK (Inst), Syros Pharmaceuticals (Inst), Astellas Pharma (Inst), Seagen (Inst), Deciphera (Inst), Moderna Therapeutics (Inst), Regeneron (Inst), Roche/Genentech (Inst), Pfizer (Inst), Laekna Therapeutics (Inst), EMD Serono (Inst), Merck (Inst), Genmab (Inst), Avenge Bio (Inst), Zentalis']}, {'Author': 'Christine Gennigens', 'Disclosures': ['Honoraria: MSD Oncology, Ipsen, Pfizer, PharmaMar, AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb/Celgene', 'Consulting or Advisory Role: MSD Oncology, Bristol Myers Squibb/Celgene, Ipsen, AstraZeneca, GlaxoSmithKline, Eisai', 'Research Funding: AstraZeneca', 'Travel, Accommodations, Expenses: Ipsen, PharmaMar, Pfizer, MSD Oncology']}, {'Author': 'David Cibula', 'Disclosures': ['Consulting or Advisory Role: AstraZeneca, Sotio, Roche, GlaxoSmithKline, Novocure, Akeso Biopharma, MSD, Mersana']}, {'Author': 'Krishnansu S. Tewari', 'Disclosures': ['Honoraria: Tesaro, Clovis Oncology, Merck, Eisai, AstraZeneca, Genmab', 'Consulting or Advisory Role: Roche/Genentech, Tesaro, Clovis Oncology, AstraZeneca', ""Speakers' Bureau: Roche/Genentech, AstraZeneca, Merck, Tesaro, Clovis Oncology, Eisai, Genmab"", 'Research Funding: AbbVie (Inst), Genentech/Roche (Inst), Morphotek (Inst), Merck (Inst), Regeneron (Inst)', 'Travel, Accommodations, Expenses: Roche/Genentech']}, {'Author': 'Kristine Madsen', 'Disclosures': ['Travel, Accommodations, Expenses: GlaxoSmithKline']}, {'Author': 'Fatih Köse', 'Disclosures': ['Honoraria: Roche (Inst), AstraZeneca (Inst), MSD/Merck (Inst), GlaxoSmithKline (Inst), Novartis (Inst), Pfizer (Inst), Takeda (Inst), Deva (Inst), Nobelpharma (Inst), Astellas Pharma (Inst), Janssen (Inst)', 'Consulting or Advisory Role: Roche, AstraZeneca, MSD/Merck, GlaxoSmithKline, Novartis, Pfizer, Takeda, Deva, Nobelpharma, Astellas Pharma, Janssen']}, {'Author': 'Amanda L. Jackson', 'Disclosures': ['Consulting or Advisory Role: Ethicon, Seagen, Sutro Biopharma, AstraZeneca']}, {'Author': 'Ingrid A. Boere', 'Disclosures': ['Consulting or Advisory Role: Tesaro/GSK (Inst), AstraZeneca (Inst)', 'Research Funding: GlaxoSmithKline (Inst)']}, {'Author': 'Giovanni Scambia', 'Disclosures': ['Consulting or Advisory Role: Clovis Oncology, AstraZeneca, PharmaMar, Roche, Tesaro', ""Speakers' Bureau: Clovis Oncology, MSD""]}, {'Author': 'Leslie M. Randall', 'Disclosures': ['Honoraria: BluPrint Oncology, PER, Curio Science', 'Consulting or Advisory Role: AstraZeneca, Clovis Oncology, GOG Foundation, Merck, Mersana, Rubius Therapeutics, Myriad Genetics, Genentech/Roche, Seagen, Eisai, Novocure, AADi, On Target Laboratories, Immunogen', ""Speakers' Bureau: Genmab/Seagen"", 'Research Funding: Genentech/Roche (Inst), On Target Laboratories (Inst), Pfizer (Inst), Aivita Biomedical (Inst), Tesaro (Inst), AstraZeneca (Inst), Merck (Inst), Akeso Biopharma (Inst), GEICO (Inst)', 'Travel, Accommodations, Expenses: AstraZeneca, Seagen, Genmab, GOG Foundation']}, {'Author': 'Jean-François Baurain', 'Disclosures': ['Consulting or Advisory Role: MSD Oncology (Inst), BMS (Inst), Novartis (Inst), Pierre Fabre (Inst), Sanofi/Regeneron (Inst), GlaxoSmithKline (Inst), AstraZeneca (Inst), Sun Pharma (Inst)']}, {'Author': 'Hannelore G. Denys', 'Disclosures': ['Consulting or Advisory Role: Pfizer (Inst), Roche (Inst), PharmaMar (Inst), AstraZeneca (Inst), Lilly (Inst), Novartis (Inst), Amgen (Inst), GlaxoSmithKline (Inst), MSD (Inst), Seagen (Inst), Gilead Sciences (Inst)', 'Research Funding: Gilead Sciences (Inst)', 'Travel, Accommodations, Expenses: Pfizer (Inst), Roche (Inst), PharmaMar (Inst), Teva (Inst), AstraZeneca (Inst), Gilead Sciences (Inst)']}, {'Author': 'Nelleke Ottevanger', 'Disclosures': ['Consulting or Advisory Role: AstraZeneca (Inst), GlaxoSmithKline (Inst), Nykode Therapeutics (Inst)']}, {'Author': 'Frédéric Forget', 'Disclosures': ['Travel, Accommodations, Expenses: Ipsen, Teva']}, {'Author': 'Camilla Mondrup Andreassen', 'Disclosures': ['Employment: Genmab', 'Stock and Other Ownership Interests: Genmab, Scandion Oncology, Novo Nordisk, Bavarian Nordic, 3M, AbbVie, Colgate Palmolive, Coloplast, Demant, Expres2ion Biotechnologies, Lundbeck, Johnson & Johnson/Janssen, Teva, Unilever']}, {'Author': 'Michael J. Chisamore', 'Disclosures': ['Employment: Merck', 'Stock and Other Ownership Interests: Merck']}, {'Author': 'Leonardo Viana Nicacio', 'Disclosures': ['Employment: Seagen', 'Stock and Other Ownership Interests: Florence Healthcare, Seagen', 'Honoraria: Seagen', 'Travel, Accommodations, Expenses: Seagen']}, {'Author': 'Ibrahima Soumaoro', 'Disclosures': ['Employment: Genmab', 'Stock and Other Ownership Interests: Genmab, Bristol Myers Squibb', 'Travel, Accommodations, Expenses: Genmab, Bristol Myers Squibb']}, {'Author': 'Bradley J. Monk', 'Disclosures': ['Leadership: US Oncology', 'Honoraria: Agenus, Akeso Biopharma, Amgen, Aravive, AstraZeneca, Clovis Oncology, Eisai, Genmab/Seattle Genetics, ImmunoGen, Iovance Biotherapeutics, Merck, Mersana, Pfizer, Puma Biotechnology, Regeneron, Roche/Genentech, Tesaro/GSK, Vascular Biogenics, GOG Foundation, Elevar Therapeutics, Novocure, Gradalis, Karyopharm Therapeutics, Bayer, EMD Serono/Merck, Sorrento Therapeutics, US Oncology, Myriad Pharmaceuticals, Novartis, OncoC4, Pieris Pharmaceuticals, Acrivon Therapeutics, Adaptimmune, HenRui, Laekna Health Care, Panavance Therapeutics, Verastem, Zentalis', 'Consulting or Advisory Role: Agenus, Akeso Biopharma, Amgen, Aravive, AstraZeneca, Clovis Oncology, Eisai, Genmab/Seattle Genetics, GOG Foundation, ImmunoGen, Iovance Biotherapeutics, Merck, Mersana, Myriad Pharmaceuticals, Pfizer, Puma Biotechnology, Regeneron, Roche/Genentech, Tesaro/GSK, Vascular Biogenics, Gradalis, Karyopharm Therapeutics, Sorrento Therapeutics, Novocure, Bayer, Elevar Therapeutics, EMD Serono/Merck, Gradalis, US Oncology, Novartis, Pieris Pharmaceuticals, OncoC4, Adaptimmune, HenRui, Laekna Health Care, Panavance Therapeutics, Verastem, Zentalis', ""Speakers' Bureau: Roche/Genentech, AstraZeneca, Clovis Oncology, Eisai, Tesaro/GSK, Merck"", 'Research Funding: Novartis (Inst), Amgen (Inst), Genentech (Inst), Lilly (Inst), Janssen (Inst), Array BioPharma (Inst), Tesaro (Inst), Morphotek (Inst), Pfizer (Inst), Advaxis (Inst), AstraZeneca (Inst), Immunogen (Inst), Regeneron (Inst), Nucana (Inst)', 'No other potential conflicts of interest were reported.']}]"
